Companies
FUJIFILM Wako
Charles River, Lonza, ACC and FUJIFILM Wako each maintain China sales and applications-support organizations serving domestic parenteral-drug and device manufacturers.
- Country
- Japan
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | 132.001 billion JPY (FY2026) | catr.jp |
| Headcount | 2,501 (as of March 2025) | asset.fujifilm.com · news.market.us |
| Capacity | Tripled production capacity of GMP-compliant pharmaceutical raw materials at the Osaka facility (as of May 2024) | fujifilm.com |
| Production site | Japan: Osaka (Amagasaki, Mie), Tokyo (Kawagoe), Aichi (Toyohashi), Hiratsuka, Harima (Ako), Miyazaki; USA: Richmond, VA and Cape Charles, VA (LAL Division) | asset.fujifilm.com · labchem-wako.fujifilm.com · specchem-wako.fujifilm.com |
| Certification | ISO 9001, ISO 14001, ISO/IEC 17025, ISO 17034 (varies by site) | labchem.fujifilm-wako.com.cn · labchem-wako.fujifilm.com · specchem-wako.fujifilm.com |
| Regulatory approval | FDA license/approval (Hirono Plant, Richmond LAL facility) | specchem-wako.fujifilm.com · wakousa.com |
| Funding | Not applicable; wholly-owned subsidiary of FUJIFILM Corporation (since 2017) medium confidence | news.market.us |
Independent sources: asset.fujifilm.com · catr.jp · labchem-wako.fujifilm.com · news.market.us · specchem-wako.fujifilm.com · wakousa.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Endotoxin testing systems | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.